Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
7.73 USD | -6.30% | -0.64% | -6.88% |
May. 09 | Cantor Fitzgerald Adjusts LifeMD's Price Target to $15 From $13, Keeps Overweight Rating | MT |
May. 08 | LifeMD, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-6.88% | 349M | - | ||
-10.33% | 28.16B | C | ||
+26.51% | 8.33B | C- | ||
+29.59% | 4.39B | B- | ||
-34.92% | 2.43B | C- | ||
-9.44% | 1.6B | - | C+ | |
-13.93% | 1.5B | B | ||
-32.84% | 1.15B | - | ||
+5.90% | 964M | C | ||
-37.56% | 872M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- LFMD Stock
- Ratings LifeMD, Inc.